홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Doxofylline

HCID 50942
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
69975-86-6
표준 SMILES
Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
InChIKey
HWXIGFIVGWUZAO-UHFFFAOYSA-N
분자식
C11H14N4O4
평균 분자량
266.25 g/mol
단동위원소 질량
266.10150494

개요

Doxofylline is an oxopurine that is a derivative of xanthine, methylated at N-1 and N-3 and carrying a 1,3-dioxolan-2-ylmethyl group at N-7, used in the treatment of asthma. It has a role as a bronchodilator agent, an anti-asthmatic drug and an antitussive. It is functionally related to a 7H-xanthine.

이름 및 식별자

우선 이름
Doxofylline
IUPAC
7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
영어명
Doxofylline
분자식
C11H14N4O4
분자량
266.25

이름 및 동의어

DOXOFYLLINE69975-86-6DoxophyllineDioxyfillineAnsimarVentaxDoxofilinaDoxofyllinumSynasmaABC 12/37-(1,3-Dioxolan-2-ylmethyl)theophyllineDTXSID7022968
이름 더 보기
abc12/3AnsirnarMAXIVENTABC 1213DoxofyliineDoxof3rlline
ABC-12/3MPM23GMO7ZNSC-7596451H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-CHEBI:94714DTXCID002968TMDO7-[(1,3-dioxolan-2-yl)methyl]-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

데이터베이스 식별자

CAS
69975-86-6
PubChem CID
50942
DTXSID
DTXSID7022968
ChEMBL
CHEMBL1527608
ChEBI
CHEBI:94714
UNII
MPM23GMO7Z
EC Number
274-239-6
Nikkaji
J23.295E

물성

구조 계산 물성보충 중

XLogP
-0.9
극성 표면적
76.9 Ų
수소 결합 공여자 수
0
수소 결합 수용자 수
5
회전 가능 결합 수
2
무거운 원자 수
19
형식 전하
0
복잡도
398

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Brochodilators

Solubility · 2건

Insoluble

>39.9 [ug/mL] (The mean of the results at pH 7.4)

물리화학적 성질

녹는점
144 · 144-146°C
끓는 점
409.46 °C · 409.46°C (rough estimate)
밀도
1.2896 · 1.2896 (rough estimate)
굴절률
1.6 · 1.6000 (estimate)
저장 조건
2 · under inert gas (nitrogen or Argon) at 2-8°C
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
물리적 상태
고체
산도 계수 (pKa)
0.42 · 0.42±0.70(Predicted)
색상
흰색에서 황백색까지
수용성
녹는
Merck
14 · 14,3438
InChI
InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
InChIKey
HWXIGFIVGWUZAO-UHFFFAOYSA-N
SMILES
N1(CC2OCCO2)C2=C(N(C)C(=O)N(C)C2=O)N=C1

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (100%)

안전 데이터

독성
LD50 in mice (mg/kg): 841 orally; 215.6 i.v.; in rats: 1022.4 orally, 445 i.p. (Franzone)
HS 번호
29399990
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36/37

화학 및 산업

약리 정보

ATC Code · 2건

R - Respiratory system

QR - Respiratory system

Protein BindingAt pH 7.4, the fraction of plasma protein binding is about 48%.
Pharmacodynamics · 1건

Doxofylline is a methylxanthine bronchodilator with potent bronchodilator activity comparable to that of theophylline. In animal studies, doxofylline demonstrated to attenuate bronchoconstriction, inflammatory actions and the release of thromboxane A2 (TXA2) when challenged with platelet-activating factor. Doxofylline does not demonstrate direct inhibition of any histone deacetylase (HDAC) enzymes or known PDE enzyme isoforms and did not act as an antagonist at A2 or A2 receptors. The affinity for adenosine A1, A2A and A2B receptors are reported to be all higher than 100 µM. It only displays an inhibitory action against PDE2A1 and antagonism at adenosine A(2A) at high concentrations. A study demonstrated that doxofylline interacts with β2-adrenoceptors to induce blood vessel relaxation and airway smooth muscle relaxation. In dog studies, doxofylline decreased airway responsiveness at a dose that did not affect heart rate and respiratory rate.

Mechanism of Action · 1건

The main mechanism of action of doxofylline is unclear. One of the mechanisms of action of is thought to arise from the inhibition of phosphodiesterase activity thus increasing the levels of cAMP and promoting smooth muscle relaxation. The interaction of doxofylline with beta-2 adrenoceptors was demonstrated by a study using nonlinear chromatography, frontal analysis and molecular docking. Serine 169 and serine 173 residues in the receptor are thought to be critical binding sites for doxofylline where hydrogen bonds are formed. Via mediating the actions of beta-2 adrenoceptors, doxofylline induces blood vessel relaxation and airway smooth muscle relaxation. There is also evidence that doxofylline may exert anti-inflammatory actions by reducing the pleurisy induced by the inflammatory mediator platelet activating factor (PAF) according to a rat study. It is suggested that doxofylline may play an important role in attenuating leukocyte diapedesis, supported by mouse preclinical studies where doxofylline administration was associated with inhibited leukocyte migration across vascular endothelial cells in vivo and in vitro.Unlike theophylline, doxofylline does not inhibit tumor necrosis factor-induced interleukin (IL)-8 secretion in ASM cells.

Biological Half-Life · 1건

Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours.

Metabolism/Metabolites · 1건

Doxofylline is thought to undergo hepatic metabolism which accounts for 90% of total drug clearance. β-hydroxymethyltheophylline was detected in the serum and urine after oral administration of 400 mg given in healthy subjects. The circulating metabolite was devoid of any significant pharmacological activity.

MeSH Pharmacological Classification · 3건

Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.

Agents that cause an increase in the expansion of a bronchus or bronchial tubes.

Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.

Absorption, Distribution and Excretion · 4건

After repeated administrations doxofylline reaches the steady-state in about 4 days. Following oral administration of 400 mg doxofylline twice daily for 5 days in adults with chronic bronchitis, the peak plasma concentrations (Cmax) at steady state ranged from 5.78 to 20.76 mcg/mL. The time to reach maximum concentration (Tmax) was 1.19 ± 0.19 hours. The absolute bioavailability of doxofylline in healthy subjects was 63 ± 25%.

Less than 4% of an orally administered dose is excreted unchanged in the urine due to extensive hepatic metabolism.

Doxofylline demonstrates a short distribution phase following intravenous administration of 100 mg given in adults with chronic bronchitis. As methylxanthines are distributed to all body compartments, doxofylline may be detected in breast milk and placenta.

Following oral administration of 400 mg doxofylline twice daily for 5 days, the total clearance was 555.2 ± 180.6 mL/min.

응용 분야 · 1건

개요Doxofylline, a xanthine bronchodilator related to theophylline, is useful in the treatment of asthma and similar bronchospastic disorders. It has minimal activity on intestinal smooth muscle and the cardiovascular system, and is reportedly devoid of the behavioral effects of theophylline.

상·하류 제품 정보

상류 원료

P-톨루엔설폰 산테오필린글리세롤 α-모노클로로히드린2,4,6-트리스(클로로메틸)-1,3,5-트리옥산클로로메틸-1,3-디옥소란2-브로모메틸-1,3-디옥소란모노에틸렌글리콜수산화나트륨Tetrabutylammomium bromide아세톤

관련 반응

1건
반응 기록 만들기
HRID 2243787 반응식
HRID 2243787생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트